We were delighted to speak with Jean-Frederic Colombel (Icahn School of Medicine at Mount Sinai, New York, US) around his talk on ‘Overcoming the Plateau in IBD Treatment’ which was presented at the virtual 2021 Crohn’s & Colitis Congress, 21-24 January, 2021.
Questions
- Could you tell us about the plateau in drug efficacy that occurs with current treatment options? (0:25)
- How important is the personalised paradigm in the treatment of IBD? (2:28)
- What are the unmet needs for biomarkers in the personalisation of IBD treatment and what has been achieved so far? (3:30)
- What is ‘Rational polypharmacy’ and what is the potential of combining therapies for overcoming the plateau in IBD treatment? (5:27)
- Is prevention during the pre-clinical phase of IBD the path to ‘breaking the ceiling’ in treatment? (9:50)
Disclosures: Jean-Frederic Colombel has received research grants from AbbVie, Janssen Pharmaceuticals and Takeda; has received payment for lectures from AbbVie, Amgen, Allergan, Bristol-Myers Squibb Company, Ferring Pharmaceuticals, Shire, Takeda and Tillots; has received consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb Company, Celgene Corporation, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Genentech, Gilead, Iterative Scopes, Ipsen, Immunic, lmtbio, Inotrem, Janssen Pharmaceuticals, Landos, LimmaTech Biologics AG, Medimmune, Merck, Novartis, O Mass, Otsuka, Pfizer, Shire, Takeda, Tigenix, Viela bio; and hold stock options in Intestinal Biotech Development.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of CCC 2021 (Virtual).
